mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70)

Coosemans, An; Tuyaerts, Sandra; Morias, Kim; Corthals, Jurgen; Heirman, Carlo; Thielemans, Kris; Gool, Stefaan W. Van; Vergote, Ignace; Amant, Frédéric

doi:10.1007/978-1-4939-3625-0_18

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, TriMix can be electroporated with the addition of mRNAs. For example, mRNA encoding Wilms' tumor gene 1 (WT1), survivin and TriMix can be electroporated [213]. In a study, patients received ipilimumab (IPI) and DCs electroporated with mRNA encoding TriMix and tumorassociated antigens tyrosinase (gp100, MAGE-A3 and MAGE-C2).…”

Section: Mrna Vaccines In Cancermentioning

confidence: 99%

mRNA vaccine: a potential therapeutic strategy

Wei¹,

et al. 2021

View full text Add to dashboard Cite

AbstractmRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, we have witnessed the development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Therefore, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nanoemulsion), naked mRNA vaccines and dendritic cells-based mRNA vaccines. The article will discuss the molecular biology of mRNA vaccines and underlying anti-virus and anti-tumor mechanisms, with an introduction of their immunological phenomena, delivery strategies, their importance on Corona Virus Disease 2019 (COVID-19) and related clinical trials against cancer and viral diseases. Finally, we will discuss the challenge of mRNA vaccines against bacterial and parasitic diseases.

show abstract

Section: Mrna Vaccines In Cancermentioning

confidence: 99%

mRNA vaccine: a potential therapeutic strategy

Wei¹,

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In fact, mRNA for TriMix, survivin, and the Wilms tumor gene 1 (WT1) can be electroporated. [ 102 ] Recently, in a study cell‐free vaccine concept is idealized by incorporating neoantigen‐based cancer vaccine using chimeric RNA‐loaded DC‐derived extracellular vesicle in mice model, which boost CD8+ T cell‐mediated anti‐tumor immunity. [ 103 ] This cell free vaccine approach may provide numerous advantages over cell‐based vaccines but its potential is yet to be discover.…”

Section: Cancer Vaccines—an Overviewmentioning

confidence: 99%

Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach

Goyal,

Chattopadhyay,

Navik

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

AbstractmRNA vaccines have long been recognized for their ability to induce robust immune responses. The discovery that mRNA vaccines may also contribute to anti‐tumor immunity has made them a promising therapeutic approach against cancer. Recent advances in understanding of immune system have been precious in developing therapeutic strategies that target pathways involved in tumor survival and progression, leading to the most reliable therapeutic strategies in cancer treatment history. Among all traditional cancer treatments, cancer immunotherapies are less toxic and more effective, even in advanced or recurrent stages of cancer. Recent advancements in genomics and machine learning algorithms give new insight into vaccine development. mRNA vaccines are designed to interfere with STING and TLR pathways, activating more CD8+ T‐cells involved in destroying tumor cells and inhibiting tumor growth. A stronger immune response can be achieved by incorporating immunological adjuvants alongside mRNA. Non‐formulated or vehicle‐based mRNA vaccines, when combined with adjuvants, efficiently express tumor antigens through antigen‐presenting cells and stimulate both innate and adaptive immune responses. Co‐delivery with additional immunotherapeutic agents, such as checkpoint inhibitors, further enhances the efficacy of mRNA vaccines. This article focused on the current clinical approaches and challenges to consider when developing mRNA‐based vaccine technology for cancer treatment.This article is protected by copyright. All rights reserved

show abstract

Production of endothelial progenitor cells from skin fibroblasts by direct reprogramming for clinical usages

Pham

Dao

et al. 2016

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

Endothelial progenitor cells (EPCs) play an important role in angiogenesis. However, they exist in limited numbers in the human body. This study was aimed to produce EPCs, for autologous transplantation, using direct reprogramming of skin fibroblasts under GMP-compliant conditions. Fibroblasts were collected and cultured from the skin in DMEM/F12 medium supplemented with 5% activated platelet-rich plasma and 1% antibiotic-antimycotic solution. They were then transfected with mRNA ETV2 and incubated in culture medium under hypoxia (5% oxygen) for 14 d. Phenotype analysis of transfected cells confirmed that single-factor ETV2 transfection successfully reprogrammed dermal fibroblasts into functional EPCs. Our results showed that ETV2 mRNA combined with hypoxia can give rise to functional EPCs. The cells exhibited functional phenotypes similar to endothelial cells derived from umbilical cord vein; they expressed CD31 and VEGFR2, and formed capillary-like structures in vitro. Moreover, these EPCs could significantly improve hindlimb ischemia in mouse models. Although the direct conversion efficacy was low (3.12 ± 0.98%), altogether our study demonstrates that functional EPCs can be produced from fibroblasts and can be used in clinical applications.

show abstract

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70)

Cited by 5 publications

References 9 publications

mRNA vaccine: a potential therapeutic strategy

mRNA vaccine: a potential therapeutic strategy

Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach

Production of endothelial progenitor cells from skin fibroblasts by direct reprogramming for clinical usages

Contact Info

Product

Resources

About